Adicet Bio, Inc.

200 Constitution Drive
Menlo Park
California
94025
United States

Tel: 310-990-3832

Email: info@adicetbio.com

Show jobs for this employer

About Adicet Bio, Inc.

JOIN US!

Adicet Bio, Inc. is a well-funded, privately held, pre-clinical stage biotechnology company that is engaged in the development of cutting-edge immunotherapies that have the potential to profoundly transform the treatment of cancer and other diseases and we are growing!

ABOUT ADICET BIO

Adicet is developing the next generation immunotherapies by generating a pipeline of allogeneic gamma delta T cell products engineering with CAR or TCR. In addition, Adicet's immune cell platform is complemented by its ability to identify and validate novel disease specific peptide-MHC targets and generates T cell receptor-like antibodies directed against these disease-specific peptide MHC complexes. Adicet Bio was founded in late 2015 and closed a Series A financing of $51M in Jan 2016. This financing was led by OrbiMed and included Novartis Venture Funds and Pontifax. In August 2016, Regeneron and Adicet Bio announced a strategic collaboration to discover and develop next-generation engineered immune-cell therapeutics, for which Adicet received a $25M upfront payment. In September 2016, Adicet Bio was recognized and named by FierceBiotech to its “Fierce 15” Biotech Companies of 2016.

9 articles with Adicet Bio, Inc.